All Studies All Outcomes

Molnupiravir for Intra-Household Prevention of COVID-19: the MOVe-AHEAD Randomized, Placebo-Controlled Trial

Alpizar et al., Journal of Infection, doi:10.1016/j.jinf.2023.08.016, MOVe-AHEAD, NCT04939428

Sep 2023

Post
Facebook

Source PDF All Studies Meta AnalysisMeta

Download Image

PEP RCT 1,527 patients showing lower COVID-19 cases with molnupiravir, without statistical significance.

Potential risks of molnupiravir include the creation of dangerous variants, and mutagenicity, carcinogenicity, teratogenicity, and embryotoxicity1-14. Multiple analyses have identified variants potentially created by molnupiravir15-19.

Important missing comments or errors? Let us know.

risk of symptomatic case, 24.2% lower, RR 0.76, p = 0.06, treatment 78 of 763 (10.2%), control 103 of 764 (13.5%), NNT 31, MITT.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

1. Swanstrom et al., Lethal mutagenesis as an antiviral strategy, Science, doi:10.1126/science.abn0048.science.org, doi.org.

2. Hadj Hassine et al., Lethal Mutagenesis of RNA Viruses and Approved Drugs with Antiviral Mutagenic Activity, Viruses, doi:10.3390/v14040841.mdpi.com, doi.org.

3. Shum, C., An investigational study into the drug-associated mutational signature in SARS-CoV-2 viruses, The University of Hong Kong, PhD Thesis, hub.hku.hk/handle/10722/344396.hku.hk.

4. Waters et al., Human genetic risk of treatment with antiviral nucleoside analog drugs that induce lethal mutagenesis: the special case of molnupiravir, Environmental and Molecular Mutagenesis, doi:10.1002/em.22471.wiley.com, doi.org.

5. Huntsman, M., An assessment of the reproductive toxicity of the anti-COVID-19 drug molnupiravir using stem cell-based embryo models, Master's Thesis, scholarspace.manoa.hawaii.edu/items/cd11342c-b4dc-44c0-8b44-ce6e3369c40b.hawaii.edu.

6. Zibat et al., N4-hydroxycytidine, the active compound of Molnupiravir, promotes SARS-CoV-2 mutagenesis and escape from a neutralizing nanobody, iScience, doi:10.1016/j.isci.2023.107786.sciencedirect.com, doi.org.

7. Shiraki et al., Convenient screening of the reproductive toxicity of favipiravir and antiviral drugs in Caenorhabditis elegans, Heliyon, doi:10.1016/j.heliyon.2024.e35331.sciencedirect.com, doi.org.

8. Gruber et al., Molnupiravir increases SARS‐CoV‐2 genome diversity and complexity: A case‐control cohort study, Journal of Medical Virology, doi:10.1002/jmv.29642.wiley.com, doi.org.

9. Marikawa et al., An active metabolite of the anti-COVID-19 drug molnupiravir impairs mouse preimplantation embryos at clinically relevant concentrations, Reproductive Toxicology, doi:10.1016/j.reprotox.2023.108475.sciencedirect.com, doi.org.

10. Rahman, M., Elucidation of the DNA repair mechanisms involved in the repair of DNA damage caused by the Arabinosides and Anti-COVID-19 drugs, tokyo-metro-u.repo.nii.ac.jp/records/2000972.ac.jp.

11. Zhou et al., β-D-N4-hydroxycytidine Inhibits SARS-CoV-2 Through Lethal Mutagenesis But Is Also Mutagenic To Mammalian Cells, The Journal of Infectious Diseases, doi:10.1093/infdis/jiab247.oup.com, doi.org.

12. Chamod et al., Molnupiravir Metabolite--N4-hydroxycytidine Causes Cytotoxicity and DNA Damage in Mammalian Cells in vitro: N4-hydroxycytidine Induced Cytotoxicity DNA Damage, Asian Medical Journal and Alternative Medicine, 23:3, asianmedjam.com/index.php/amjam/article/view/1448.asianmedjam.com.

13. Standing et al., Randomized controlled trial of molnupiravir SARS-CoV-2 viral and antibody response in at-risk adult outpatients, Nature Communications, doi:10.1038/s41467-024-45641-0.nature.com, doi.org.

14. Mori et al., Reactive oxygen species-mediated cytotoxic and DNA-damaging mechanism of N4-hydroxycytidine, a metabolite of the COVID-19 therapeutic drug molnupiravir, Free Radical Research, doi:10.1080/10715762.2025.2469738.tandfonline.com, doi.org.

15. Focosi et al., The fitness of molnupiravir-signed SARS-CoV-2 variants: imputation analysis based on prescription counts and GISAID analyses by country, Intervirology, doi:10.1159/000540282.karger.com, doi.org.

16. Sanderson et al., A molnupiravir-associated mutational signature in global SARS-CoV-2 genomes, Nature, doi:10.1038/s41586-023-06649-6.nature.com, doi.org.

17. Fountain-Jones et al., Effect of molnupiravir on SARS-CoV-2 evolution in immunocompromised patients: a retrospective observational study, The Lancet Microbe, doi:10.1016/S2666-5247(23)00393-2.sciencedirect.com, doi.org.

18. Kosakovsky Pond et al., Anti-COVID drug accelerates viral evolution, Nature, doi:10.1038/d41586-023-03248-3.nature.com, doi.org.

19. twitter.com, twitter.com/LongDesertTrain/status/1597353291868155906.twitter.com/LongDesertTrain/status/1597353291868155906.

Alpizar et al., 8 Sep 2023, Double Blind Randomized Controlled Trial, placebo-controlled, multiple countries, peer-reviewed, 18 authors, trial NCT04939428 (history) (MOVe-AHEAD).

This Paper Molnupiravir All

DOI record: { "DOI": "10.1016/j.jinf.2023.08.016", "ISSN": [ "0163-4453" ], "URL": "http://dx.doi.org/10.1016/j.jinf.2023.08.016", "alternative-id": [ "S0163445323005005" ], "assertion": [ { "label": "This article is maintained by", "name": "publisher", "value": "Elsevier" }, { "label": "Article Title", "name": "articletitle", "value": "Molnupiravir for intra-household prevention of COVID-19: The MOVe-AHEAD randomized, placebo-controlled trial" }, { "label": "Journal Title", "name": "journaltitle", "value": "Journal of Infection" }, { "label": "CrossRef DOI link to publisher maintained version", "name": "articlelink", "value": "https://doi.org/10.1016/j.jinf.2023.08.016" }, { "label": "Content Type", "name": "content_type", "value": "article" }, { "label": "Copyright", "name": "copyright", "value": "© 2023 Merck Sharp & Dohme LLC., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA and The Author(s). Published by Elsevier Ltd on behalf of The British Infection Association." } ], "author": [ { "affiliation": [], "family": "Alpizar", "given": "Sady A.", "sequence": "first" }, { "affiliation": [], "family": "Accini", "given": "Jose", "sequence": "additional" }, { "affiliation": [], "family": "Anderson", "given": "Duane C.", "sequence": "additional" }, { "affiliation": [], "family": "Eysa", "given": "Basem", "sequence": "additional" }, { "ORCID": "http://orcid.org/0000-0003-3585-9475", "affiliation": [], "authenticated-orcid": false, "family": "Medina-Piñón", "given": "Isaí", "sequence": "additional" }, { "affiliation": [], "family": "Ohmagari", "given": "Norio", "sequence": "additional" }, { "affiliation": [], "family": "Ostrovskyy", "given": "Mykola M.", "sequence": "additional" }, { "affiliation": [], "family": "Aggrey-Amable", "given": "Angela", "sequence": "additional" }, { "affiliation": [], "family": "Beck", "given": "Karen", "sequence": "additional" }, { "ORCID": "http://orcid.org/0000-0002-3947-6546", "affiliation": [], "authenticated-orcid": false, "family": "Byrne", "given": "Dana", "sequence": "additional" }, { "ORCID": "http://orcid.org/0009-0007-6755-4058", "affiliation": [], "authenticated-orcid": false, "family": "Grayson", "given": "Staci", "sequence": "additional" }, { "affiliation": [], "family": "Hwang", "given": "Peggy M.T.", "sequence": "additional" }, { "affiliation": [], "family": "Lonchar", "given": "Julia D.", "sequence": "additional" }, { "affiliation": [], "family": "Strizki", "given": "Julie", "sequence": "additional" }, { "affiliation": [], "family": "Xu", "given": "Yayun", "sequence": "additional" }, { "affiliation": [], "family": "Paschke", "given": "Amanda", "sequence": "additional" }, { "affiliation": [], "family": "De Anda", "given": "Carisa S.", "sequence": "additional" }, { "affiliation": [], "family": "Sears", "given": "Pamela S.", "sequence": "additional" } ], "container-title": "Journal of Infection", "container-title-short": "Journal of Infection", "content-domain": { "crossmark-restriction": true, "domain": [ "clinicalkey.fr", "clinicalkey.jp", "clinicalkey.es", "clinicalkey.com.au", "clinicalkey.com", "journalofinfection.com", "elsevier.com", "sciencedirect.com" ] }, "created": { "date-parts": [ [ 2023, 9, 9 ] ], "date-time": "2023-09-09T22:16:31Z", "timestamp": 1694297791000 }, "deposited": { "date-parts": [ [ 2023, 10, 19 ] ], "date-time": "2023-10-19T23:06:49Z", "timestamp": 1697756809000 }, "funder": [ { "DOI": "10.13039/100009947", "doi-asserted-by": "publisher", "name": "Merck Sharp and Dohme" } ], "indexed": { "date-parts": [ [ 2024, 4, 2 ] ], "date-time": "2024-04-02T10:54:22Z", "timestamp": 1712055262731 }, "is-referenced-by-count": 2, "issue": "5", "issued": { "date-parts": [ [ 2023, 11 ] ] }, "journal-issue": { "issue": "5", "published-print": { "date-parts": [ [ 2023, 11 ] ] } }, "language": "en", "license": [ { "URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "content-version": "tdm", "delay-in-days": 0, "start": { "date-parts": [ [ 2023, 11, 1 ] ], "date-time": "2023-11-01T00:00:00Z", "timestamp": 1698796800000 } }, { "URL": "http://creativecommons.org/licenses/by-nc-nd/4.0/", "content-version": "vor", "delay-in-days": 0, "start": { "date-parts": [ [ 2023, 9, 18 ] ], "date-time": "2023-09-18T00:00:00Z", "timestamp": 1694995200000 } } ], "link": [ { "URL": "https://api.elsevier.com/content/article/PII:S0163445323005005?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://api.elsevier.com/content/article/PII:S0163445323005005?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining" } ], "member": "78", "original-title": [], "page": "392-402", "prefix": "10.1016", "published": { "date-parts": [ [ 2023, 11 ] ] }, "published-print": { "date-parts": [ [ 2023, 11 ] ] }, "publisher": "Elsevier BV", "reference": [ { "key": "10.1016/j.jinf.2023.08.016_bib1", "unstructured": "World Health Organization. WHO Coronavirus (COVID-19) Dashboard (Updated September 05, 2023). World Health Organization (WHO); 2023. Available at: https://covid19.who.int. [Accessed on September 12, 2023]." }, { "DOI": "10.1016/j.euroneuro.2021.10.004", "article-title": "Results of the COVID-19 mental health international for the general population (COMET-G) study", "author": "Fountoulakis", "doi-asserted-by": "crossref", "first-page": "21", "journal-title": "Eur Neuropsychopharmacol", "key": "10.1016/j.jinf.2023.08.016_bib2", "volume": "54", "year": "2022" }, { "DOI": "10.1001/jama.2022.18931", "article-title": "Estimated global proportions of individuals with persistent fatigue, cognitive, and respiratory symptom clusters following symptomatic COVID-19 in 2020 and 2021", "author": "Wulf Hanson", "doi-asserted-by": "crossref", "first-page": "1604", "issue": "16", "journal-title": "JAMA", "key": "10.1016/j.jinf.2023.08.016_bib3", "volume": "328", "year": "2022" }, { "DOI": "10.1016/S0140-6736(21)02796-3", "article-title": "Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020-21", "doi-asserted-by": "crossref", "first-page": "1513", "issue": "10334", "journal-title": "Lancet", "key": "10.1016/j.jinf.2023.08.016_bib4", "volume": "399", "year": "2022" }, { "DOI": "10.1016/S0140-6736(21)02143-7", "article-title": "Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic", "doi-asserted-by": "crossref", "first-page": "1700", "issue": "10312", "journal-title": "Lancet", "key": "10.1016/j.jinf.2023.08.016_bib5", "volume": "398", "year": "2021" }, { "DOI": "10.3389/fpubh.2023.1112383", "article-title": "Post-acute COVID-19 symptom risk in hospitalized and non-hospitalized COVID-19 survivors: A systematic review and meta-analysis", "author": "Yuan", "doi-asserted-by": "crossref", "journal-title": "Front Public Health", "key": "10.1016/j.jinf.2023.08.016_bib6", "volume": "11", "year": "2023" }, { "DOI": "10.1016/j.eclinm.2021.101019", "article-title": "Characterizing long COVID in an international cohort: 7 months of symptoms and their impact", "author": "Davis", "doi-asserted-by": "crossref", "journal-title": "EClinicalMedicine", "key": "10.1016/j.jinf.2023.08.016_bib7", "volume": "38", "year": "2021" }, { "DOI": "10.7326/M22-0729", "article-title": "Effect of molnupiravir on biomarkers, respiratory interventions, and medical services in COVID-19: A randomized, placebo-controlled trial", "author": "Johnson", "doi-asserted-by": "crossref", "first-page": "1126", "issue": "8", "journal-title": "Ann Intern Med", "key": "10.1016/j.jinf.2023.08.016_bib8", "volume": "175", "year": "2022" }, { "DOI": "10.1007/s40273-022-01168-0", "article-title": "Cost-effectiveness analysis of molnupiravir versus best supportive care for the treatment of outpatient COVID-19 in adults in the US", "author": "Goswami", "doi-asserted-by": "crossref", "first-page": "699", "issue": "7", "journal-title": "Pharmacoeconomics", "key": "10.1016/j.jinf.2023.08.016_bib9", "volume": "40", "year": "2022" }, { "author": "Aleem", "key": "10.1016/j.jinf.2023.08.016_bib10", "series-title": "Emerging variants of SARS-CoV-2 and novel therapeutics against coronavirus (COVID-19)", "year": "2023" }, { "author": "Cascella", "key": "10.1016/j.jinf.2023.08.016_bib11", "series-title": "Features, evaluation, and treatment of coronavirus (COVID-19)", "year": "2022" }, { "article-title": "The challenge of asymptomatic carriers of COVID-19: a rapid review of literature", "author": "Albavera-Hernandez", "first-page": "649", "issue": "6", "journal-title": "Rev Salud Publica", "key": "10.1016/j.jinf.2023.08.016_bib12", "volume": "22", "year": "2023" }, { "DOI": "10.1016/j.ijid.2023.03.025", "article-title": "Impact of public health and social measures on contact dynamics during a SARS-CoV-2 Omicron variant outbreak in Quanzhou, China, March to April 2022", "author": "Guo", "doi-asserted-by": "crossref", "first-page": "46", "journal-title": "Int J Infect Dis", "key": "10.1016/j.jinf.2023.08.016_bib13", "volume": "131", "year": "2023" }, { "DOI": "10.1136/bmjpo-2022-001718", "article-title": "Systematic review of outbreaks of COVID-19 within households in the European region when the child is the index case", "author": "Vardavas", "doi-asserted-by": "crossref", "first-page": "1", "journal-title": "BMJ Paediatr Open", "key": "10.1016/j.jinf.2023.08.016_bib14", "volume": "7", "year": "2023" }, { "article-title": "Household transmission of SARS-CoV-2 during the Omicron wave in Shanghai, China: a case-ascertained study", "author": "Wei", "issue": "2", "journal-title": "Influenza Other Respir Virus", "key": "10.1016/j.jinf.2023.08.016_bib15", "volume": "17", "year": "2023" }, { "DOI": "10.1016/j.cmi.2021.10.015", "article-title": "Transmission of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) from pre and asymptomatic infected individuals: a systematic review", "author": "Jefferson", "doi-asserted-by": "crossref", "first-page": "178", "issue": "2", "journal-title": "Clin Microbiol Infect", "key": "10.1016/j.jinf.2023.08.016_bib16", "volume": "28", "year": "2022" }, { "DOI": "10.1016/j.jinf.2022.10.027", "article-title": "Viral dynamics of the SARS-CoV-2 Omicron variant among household contacts with 2 or 3 COVID-19 vaccine doses", "author": "Kandel", "doi-asserted-by": "crossref", "first-page": "666", "issue": "6", "journal-title": "J Infect", "key": "10.1016/j.jinf.2023.08.016_bib17", "volume": "85", "year": "2022" }, { "DOI": "10.1111/irv.13002", "article-title": "Transmission of SARS-CoV-2 in standardised first few X cases and household transmission investigations: a systematic review and meta-analysis", "author": "Lewis", "doi-asserted-by": "crossref", "first-page": "803", "issue": "5", "journal-title": "Influenza Other Respir Virus", "key": "10.1016/j.jinf.2023.08.016_bib18", "volume": "16", "year": "2022" }, { "DOI": "10.1093/cid/ciad074", "article-title": "Infection-induced immunity is associated with protection against SARS-CoV-2 infection and decreased infectivity", "author": "Frutos", "doi-asserted-by": "crossref", "first-page": "2126", "issue": "12", "journal-title": "Clin Infect Dis", "key": "10.1016/j.jinf.2023.08.016_bib19", "volume": "76", "year": "2023" }, { "DOI": "10.1093/ofid/ofac676", "article-title": "Association between population-level factors and household secondary attack rate of SARS-CoV-2: a systematic review and meta-analysis", "author": "Wang", "doi-asserted-by": "crossref", "first-page": "ofac676", "issue": "1", "journal-title": "Open Forum Infect Dis", "key": "10.1016/j.jinf.2023.08.016_bib20", "volume": "10", "year": "2023" }, { "DOI": "10.1038/s41467-022-31441-x", "article-title": "Revisiting COVID-19 vaccine hesitancy around the world using data from 23 countries in 2021", "author": "Lazarus", "doi-asserted-by": "crossref", "first-page": "3801", "issue": "1", "journal-title": "Nat Commun", "key": "10.1016/j.jinf.2023.08.016_bib21", "volume": "13", "year": "2022" }, { "DOI": "10.1016/S0140-6736(21)00306-8", "article-title": "Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment", "author": "Wouters", "doi-asserted-by": "crossref", "first-page": "1023", "issue": "10278", "journal-title": "Lancet", "key": "10.1016/j.jinf.2023.08.016_bib22", "volume": "397", "year": "2021" }, { "DOI": "10.3389/fpubh.2023.1078009", "article-title": "COVID-19 vaccine hesitancy among parents in Low- and Middle-Income Countries: a meta-analysis", "author": "Abu El Kheir-Mataria", "doi-asserted-by": "crossref", "first-page": "1078009", "journal-title": "Front Public Health", "key": "10.1016/j.jinf.2023.08.016_bib23", "volume": "11", "year": "2023" }, { "DOI": "10.1016/S0140-6736(22)00152-0", "article-title": "Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression", "author": "Feikin", "doi-asserted-by": "crossref", "first-page": "924", "issue": "10328", "journal-title": "Lancet", "key": "10.1016/j.jinf.2023.08.016_bib24", "volume": "399", "year": "2022" }, { "DOI": "10.1016/j.ajpath.2022.01.007", "article-title": "Signals of significantly increased vaccine breakthrough, decreased hospitalization rates, and less severe disease in patients with coronavirus disease 2019 caused by the Omicron variant of Severe Acute Respiratory Syndrome Coronavirus 2 in Houston, Texas", "author": "Christensen", "doi-asserted-by": "crossref", "first-page": "642", "issue": "4", "journal-title": "Am J Pathol", "key": "10.1016/j.jinf.2023.08.016_bib25", "volume": "192", "year": "2022" }, { "DOI": "10.1002/jmv.27871", "article-title": "Clinical manifestations of COVID-19 breakthrough infections: a systematic review and meta-analysis", "author": "Lee", "doi-asserted-by": "crossref", "first-page": "4234", "issue": "9", "journal-title": "J Med Virol", "key": "10.1016/j.jinf.2023.08.016_bib26", "volume": "94", "year": "2022" }, { "DOI": "10.1017/S0950268823000249", "article-title": "Characteristics of patients with SARS-COV-2 PCR re-positivity after recovering from COVID-19", "author": "Hu", "doi-asserted-by": "crossref", "journal-title": "Epidemiol Infect", "key": "10.1016/j.jinf.2023.08.016_bib27", "volume": "151", "year": "2023" }, { "DOI": "10.3390/ijerph20043335", "article-title": "Severity and outcomes of SARS-CoV-2 reinfection compared with primary infection: A systematic review and meta-analysis", "author": "Deng", "doi-asserted-by": "crossref", "first-page": "4", "journal-title": "Int J Environ Res Public Health", "key": "10.1016/j.jinf.2023.08.016_bib28", "volume": "20", "year": "2023" }, { "DOI": "10.1007/s40121-022-00753-2", "article-title": "Durability of vaccine-induced and natural immunity against COVID-19: a narrative review", "author": "Pooley", "doi-asserted-by": "crossref", "first-page": "367", "issue": "2", "journal-title": "Infect Dis Ther", "key": "10.1016/j.jinf.2023.08.016_bib29", "volume": "12", "year": "2023" }, { "DOI": "10.1086/381128", "article-title": "Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis", "author": "Hayden", "doi-asserted-by": "crossref", "first-page": "440", "issue": "3", "journal-title": "J Infect Dis", "key": "10.1016/j.jinf.2023.08.016_bib30", "volume": "189", "year": "2004" }, { "DOI": "10.1056/NEJMoa1915341", "article-title": "Baloxavir marboxil for prophylaxis against influenza in household contacts", "author": "Ikematsu", "doi-asserted-by": "crossref", "first-page": "309", "issue": "4", "journal-title": "N Engl J Med", "key": "10.1016/j.jinf.2023.08.016_bib31", "volume": "383", "year": "2020" }, { "article-title": "Pre-exposure prophylaxis for viral infections other than HIV", "author": "Soriano", "first-page": "362", "issue": "3", "journal-title": "Infez Med", "key": "10.1016/j.jinf.2023.08.016_bib32", "volume": "30", "year": "2022" }, { "key": "10.1016/j.jinf.2023.08.016_bib33", "unstructured": "United States Food and Drug Administration. FDA authorizes bamlanivimab and etesevimab monoclonal antibody therapy for post-exposure prophylaxis (prevention) for COVID-19. U.S. Food & Drug Administration (FDA); 2021 (updated September 16, 2021). Available at: https://www.fda.gov/drugs/drug-safety-and-availability/fda-authorizes-bamlanivimab-and-etesevimab-monoclonal-antibody-therapy-post-exposure-prophylaxis. [Accessed on: September 13, 2023]." }, { "DOI": "10.1056/NEJMoa2109682", "article-title": "Subcutaneous REGEN-COV antibody combination to prevent Covid-19", "author": "O'Brien", "doi-asserted-by": "crossref", "first-page": "1184", "issue": "13", "journal-title": "N Engl J Med", "key": "10.1016/j.jinf.2023.08.016_bib34", "volume": "385", "year": "2021" }, { "key": "10.1016/j.jinf.2023.08.016_bib35", "unstructured": "National Institues of Health. Coronavirus Disease 2019 (COVID-19) treatment guidelines (Updated August 22, 2023). National Institues of Health (NIH); 2023. Available at https://www.covid19treatmentguidelines.nih.gov. [Accessed on: September 13, 2023]." }, { "DOI": "10.1128/AAC.02428-20", "article-title": "Human safety, tolerability, and pharmacokinetics of molnupiravir, a novel broad-spectrum oral antiviral agent with activity against SARS-CoV-2", "author": "Painter", "doi-asserted-by": "crossref", "issue": "5", "journal-title": "Antimicrob Agents Chemother", "key": "10.1016/j.jinf.2023.08.016_bib36", "volume": "65", "year": "2021" }, { "DOI": "10.1126/scitranslmed.abb5883", "article-title": "An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice", "author": "Sheahan", "doi-asserted-by": "crossref", "issue": "541", "journal-title": "Sci Transl Med", "key": "10.1016/j.jinf.2023.08.016_bib37", "volume": "12", "year": "2020" }, { "DOI": "10.1038/s41586-021-03312-w", "article-title": "SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801", "author": "Wahl", "doi-asserted-by": "crossref", "first-page": "451", "journal-title": "Nature", "key": "10.1016/j.jinf.2023.08.016_bib38", "volume": "591", "year": "2021" }, { "DOI": "10.1128/AAC.00766-18", "article-title": "Orally efficacious broad-spectrum ribonucleoside analog inhibitor of influenza and respiratory syncytial viruses", "author": "Yoon", "doi-asserted-by": "crossref", "issue": "8", "journal-title": "Antimicrob Agents Chemother", "key": "10.1016/j.jinf.2023.08.016_bib39", "volume": "62", "year": "2018" }, { "DOI": "10.1056/NEJMoa2116044", "article-title": "Molnupiravir for oral treatment of COVID-19 in nonhospitalized patients", "author": "Jayk Bernal", "doi-asserted-by": "crossref", "first-page": "509", "issue": "6", "journal-title": "N Engl J Med", "key": "10.1016/j.jinf.2023.08.016_bib40", "volume": "386", "year": "2022" }, { "DOI": "10.1172/jci.insight.160108", "article-title": "Molnupiravir inhibits SARS-CoV-2 variants including Omicron in the hamster model", "author": "Rosenke", "doi-asserted-by": "crossref", "first-page": "13", "journal-title": "JCI Insight", "key": "10.1016/j.jinf.2023.08.016_bib41", "volume": "7", "year": "2022" }, { "DOI": "10.1093/infdis/jiab361", "article-title": "Molnupiravir inhibits the replication of the emerging SARS-CoV-2 variants of concern (VoCs) in a hamster infection model", "author": "Abdelnabi", "doi-asserted-by": "crossref", "first-page": "749", "issue": "5", "journal-title": "J Infect Dis", "key": "10.1016/j.jinf.2023.08.016_bib42", "volume": "224", "year": "2021" }, { "DOI": "10.1038/s41467-022-32045-1", "article-title": "SARS-CoV-2 VOC type and biological sex affect molnupiravir efficacy in severe COVID-19 dwarf hamster model", "author": "Lieber", "doi-asserted-by": "crossref", "first-page": "4416", "issue": "1", "journal-title": "Nat Commun", "key": "10.1016/j.jinf.2023.08.016_bib43", "volume": "13", "year": "2022" }, { "DOI": "10.1056/NEJMc2119407", "article-title": "Efficacy of antibodies and antiviral drugs against Covid-19 Omicron variant", "author": "Takashita", "doi-asserted-by": "crossref", "first-page": "995", "issue": "10", "journal-title": "N Engl J Med", "key": "10.1016/j.jinf.2023.08.016_bib44", "volume": "386", "year": "2022" }, { "DOI": "10.1128/JVI.01348-19", "article-title": "Small-molecule antiviral beta-d-N (4)-hydroxycytidine inhibits a proofreading-intact coronavirus with a high genetic barrier to resistance", "author": "Agostini", "doi-asserted-by": "crossref", "issue": "24", "journal-title": "J Virol", "key": "10.1016/j.jinf.2023.08.016_bib45", "volume": "93", "year": "2019" }, { "DOI": "10.1128/JVI.01965-17", "article-title": "β-d-N4-hydroxycytidine is a potent anti-alphavirus compound that induces a high level of mutations in the viral genome", "author": "Urakova", "doi-asserted-by": "crossref", "issue": "3", "journal-title": "J Virol", "key": "10.1016/j.jinf.2023.08.016_bib46", "volume": "92", "year": "2018" }, { "DOI": "10.1016/S0140-6736(22)02597-1", "article-title": "Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial", "author": "Butler", "doi-asserted-by": "crossref", "first-page": "281", "issue": "10373", "journal-title": "Lancet", "key": "10.1016/j.jinf.2023.08.016_bib47", "volume": "401", "year": "2023" }, { "DOI": "10.1016/j.jinf.2023.02.012", "article-title": "Real-world effectiveness of molnupiravir, nirmatrelvir-ritonavir, and sotrovimab on preventing hospital admission among higher-risk patients with COVID-19 in Wales: A retrospective cohort study", "author": "Evans", "doi-asserted-by": "crossref", "first-page": "352", "issue": "4", "journal-title": "J Infect", "key": "10.1016/j.jinf.2023.08.016_bib48", "volume": "86", "year": "2023" }, { "DOI": "10.1038/s41596-021-00536-y", "article-title": "Quantification of SARS-CoV-2 neutralizing antibody by wild-type plaque reduction neutralization, microneutralization and pseudotyped virus neutralization assays", "author": "Bewley", "doi-asserted-by": "crossref", "first-page": "3114", "issue": "6", "journal-title": "Nat Protoc", "key": "10.1016/j.jinf.2023.08.016_bib49", "volume": "16", "year": "2021" }, { "DOI": "10.1259/0007-1285-44-526-793", "article-title": "Repeated assessment of results in clinical trials of cancer treatment", "author": "Haybittle", "doi-asserted-by": "crossref", "first-page": "793", "issue": "526", "journal-title": "Br J Radio", "key": "10.1016/j.jinf.2023.08.016_bib50", "volume": "44", "year": "1971" }, { "DOI": "10.1038/bjc.1976.220", "article-title": "Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design", "author": "Peto", "doi-asserted-by": "crossref", "first-page": "585", "issue": "6", "journal-title": "Br J Cancer", "key": "10.1016/j.jinf.2023.08.016_bib51", "volume": "34", "year": "1976" }, { "DOI": "10.1093/cid/ciaa1558", "article-title": "The household secondary attack rate of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): a rapid review", "author": "Fung", "doi-asserted-by": "crossref", "first-page": "S138", "issue": "Suppl.2", "journal-title": "Clin Infect Dis", "key": "10.1016/j.jinf.2023.08.016_bib52", "volume": "73", "year": "2021" }, { "DOI": "10.1371/journal.pone.0240205", "article-title": "What do we know about SARS-CoV-2 transmission? A systematic review and meta-analysis of the secondary attack rate and associated risk factors", "author": "Koh", "doi-asserted-by": "crossref", "issue": "10", "journal-title": "PLoS One", "key": "10.1016/j.jinf.2023.08.016_bib53", "volume": "15", "year": "2020" }, { "DOI": "10.1001/jamanetworkopen.2020.31756", "article-title": "Household transmission of SARS-CoV-2: a systematic review and meta-analysis", "author": "Madewell", "doi-asserted-by": "crossref", "issue": "12", "journal-title": "JAMA Netw Open", "key": "10.1016/j.jinf.2023.08.016_bib54", "volume": "3", "year": "2020" }, { "DOI": "10.7326/M20-2671", "article-title": "Contact settings and risk for transmission in 3410 close contacts of patients With COVID-19 in Guangzhou, China: a Prospective Cohort Study", "author": "Luo", "doi-asserted-by": "crossref", "first-page": "879", "issue": "11", "journal-title": "Ann Intern Med", "key": "10.1016/j.jinf.2023.08.016_bib55", "volume": "173", "year": "2020" }, { "DOI": "10.1128/mbio.02916-22", "article-title": "Why molnupiravir fails in hospitalized patients", "author": "Brown", "doi-asserted-by": "crossref", "issue": "6", "journal-title": "mBio", "key": "10.1016/j.jinf.2023.08.016_bib56", "volume": "13", "year": "2022" }, { "DOI": "10.1016/j.resinv.2023.01.002", "article-title": "COVID-19 symptom-onset to diagnosis and diagnosis to treatment intervals are significant predictors of disease progression and hospitalization in high-risk patients: a real world analysis", "author": "Shimizu", "doi-asserted-by": "crossref", "first-page": "220", "issue": "2", "journal-title": "Respir Invest", "key": "10.1016/j.jinf.2023.08.016_bib57", "volume": "61", "year": "2023" }, { "article-title": "Molnupiravir and risk of post-acute sequelae of Covid-19: cohort study", "author": "Xie", "journal-title": "BMJ", "key": "10.1016/j.jinf.2023.08.016_bib58", "volume": "381", "year": "2023" }, { "key": "10.1016/j.jinf.2023.08.016_bib59", "unstructured": "Pfizer, Inc. FDA Briefing Document. NDA# 217188. Drug name: nirmatrelvir tablets and ritonavir tablets copackaged for oral use. Pfizer, Inc.; March 16, 2023." }, { "key": "10.1016/j.jinf.2023.08.016_bib60", "unstructured": "Pfizer, Inc. PAXLOVID (nirmaltrevir [PF-07321332] tablets; ritonavir tablets). NDA 217188. Advisory committee briefing materials. Pfizer, Inc.; March 16, 2023." }, { "DOI": "10.1126/scitranslmed.abl7430", "article-title": "A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus", "author": "Fischer", "doi-asserted-by": "crossref", "first-page": "eabl7430", "issue": "628", "journal-title": "Sci Transl Med", "key": "10.1016/j.jinf.2023.08.016_bib61", "volume": "14", "year": "2022" }, { "article-title": "SARS-CoV-2 viral load and shedding kinetics", "author": "Puhach", "first-page": "147", "issue": "3", "journal-title": "Nat Rev Microbiol", "key": "10.1016/j.jinf.2023.08.016_bib62", "volume": "21", "year": "2023" }, { "DOI": "10.1086/345722", "article-title": "Zanamivir prophylaxis: an effective strategy for the prevention of influenza types A and B within households", "author": "Monto", "doi-asserted-by": "crossref", "first-page": "1582", "issue": "11", "journal-title": "J Infect Dis", "key": "10.1016/j.jinf.2023.08.016_bib63", "volume": "186", "year": "2002" } ], "reference-count": 63, "references-count": 63, "relation": {}, "resource": { "primary": { "URL": "https://linkinghub.elsevier.com/retrieve/pii/S0163445323005005" } }, "score": 1, "short-title": [], "source": "Crossref", "subject": [ "Infectious Diseases", "Microbiology (medical)" ], "subtitle": [], "title": "Molnupiravir for intra-household prevention of COVID-19: The MOVe-AHEAD randomized, placebo-controlled trial", "type": "journal-article", "update-policy": "http://dx.doi.org/10.1016/elsevier_cm_policy", "volume": "87" }

Download Image

Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit

Post

@CovidAnalysis

FAQ

Public domain CC0 1.0